DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. The company continues to build a diverse pipeline, including candidates for the treatment of metabolic diseases (diabetes), and pain.
Presently DARA has two drug candidates with cleared IND’s (Investigational New Drug) Applications from the US FDA. One of these drug candidates KRN5500 has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis.
DARA’s experienced team efficiently advances product candidates through clinical development, yielding commercially and medically attractive therapeutics. The company’s strategy exploits the need of midsize and large pharmaceutical companies to fill their sparse pipelines. The development and liquidity strategy for each entity varies according to market conditions, stage of development, and competitive market landscape.
To best manage the risks of the Company, DARA utilizes a stringent due diligence process anchored by having knowledge of a drug or technology candidate’s attributes that will most likely yield commercial success. The due diligence, development and commercial expertise resident at DARA help ensure that we identify the highest caliber candidates. Precise, targeted research is then conducted to form a solid basis for future marketing approval and medical and commercial success.
The DARA Biosciences senior management team has substantial experience in the formation of pharmaceutical, biopharmaceutical and medical device companies. They understand how the development and commercialization processes come together to build successful medical brands. Collectively, the leadership team has formed more than 10 companies, most of which have gained access to public markets or provided a significant return to private investors.